Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | APAF1 | O14727 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 3/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | PLK4 | O00444 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20380015 | 0.85 | FGFR1 (0.36) | FGFR1FGFR2FGFR3MAPTKDM4E | |
| SCHEMBL21373655 | 0.82 | FGFR1 (0.40) | FGFR1FGFR2FGFR3MAPTKDM4E | |
| SCHEMBL21373503 | 0.80 | KDM4E (0.36) | FGFR1FGFR2FGFR3MAPTKDM4E | |
| SCHEMBL21373664 | 0.78 | FGFR1 (0.40) | FGFR1FGFR2FGFR3MAPTKDM4E | |
| SCHEMBL21373658 | 0.77 | MAP3K11 (0.36) | FGFR1FGFR2FGFR3MAPTKDM4E | |
| SCHEMBL21373644 | 0.76 | QPCT (0.40) | FGFR1FGFR2FGFR3MAPK1METAP2 | |
| SCHEMBL21373555 | 0.76 | DYRK1A (0.44) | FGFR1FGFR2FGFR3MAPTKDM4E | |
| SCHEMBL20379081 | 0.76 | NOS1 (0.44) | FGFR1FGFR2FGFR3MAPTKDM4E | |
| SCHEMBL21373603 | 0.76 | KDM4E (0.40) | FGFR1FGFR2FGFR3MAPTKDM4E | |
| SCHEMBL20379065 | 0.75 | MAP3K11 (0.36) | FGFR1FGFR2FGFR3MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3568133-B1 | CELL-PROTECTIVE COMPOUNDS AND THEIR USE | ETH ZUERICH (CH) | 2023-12-13 | — | — | EP | claimed |
| US-11628159-B2 | Cell-protective compounds and their use | ETH ZURICH (CH) | 2023-04-18 | — | — | US | claimed |
| US-20210015793-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH ZURICH (CH) | 2021-01-21 | — | — | US | claimed |
| US-20190343802-A1 | CELL-PROTECTIVE COMPOUNDS AND THEIR USE | ETH Zürich (CH) | 2019-11-14 | — | — | US | claimed |
| EP-3543231-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH Zurich (CH) | 2019-09-25 | — | — | EP | claimed |
| EP-3568133-B1 | CELL-PROTECTIVE COMPOUNDS AND THEIR USE | ETH ZUERICH (CH) | 2023-12-13 | — | — | EP | disclosed |
| CN-116462666-A | Cytoprotective compounds and uses thereof | 瑞士苏黎世联邦理工学院 | 2023-07-21 | — | — | CN | disclosed |
| US-11628159-B2 | Cell-protective compounds and their use | ETH ZURICH (CH) | 2023-04-18 | — | — | US | disclosed |
| US-20210015793-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH ZURICH (CH) | 2021-01-21 | — | — | US | disclosed |
| US-20190343802-A1 | CELL-PROTECTIVE COMPOUNDS AND THEIR USE | ETH Zürich (CH) | 2019-11-14 | — | — | US | disclosed |
| EP-3543231-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH Zurich (CH) | 2019-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343802-A1 | CELL-PROTECTIVE COMPOUNDS AND THEIR USE | SRPK2, SRSF2, SRPK1 | FGFR1 2106/4885FGFR2 1989/4885FGFR3 3164/4885 |
| US-20210015793-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | PPT1, SPTLC1, LPCAT1 | FGFR1 4111/4885FGFR2 4755/4885FGFR3 4419/4885 |
| US-11628159-B2 | Cell-protective compounds and their use | SRPK2, SRSF2, SRPK1 | FGFR1 2106/4885FGFR2 1989/4885FGFR3 3164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.